It has been a busy month for Allergan, the global pharmaceutical company focused on eye care among other things. The company acquired AqueSys in an all-cash transaction earlier this month, according to a press release.
AqueSys, a glaucoma treatment company, specialized in developing surgical products to preserve vision for glaucoma patients. The acquisition included a $300 million up-front payment and potential regulatory approval and commercialization milestone payments for AqueSys’ Xen45, according to Ocular Surgery News. Xen45 is a minimally invasive implantable shunt that reduces intraocular pressure for glaucoma patients.
“The acquisition of AqueSys and Xen45 is highly complementary to our leadership position in eye care and underscores our commitment to develop and commercialize treatments that advance care and add value for ophthalmologists and their patients,” said Brent Saunders, CEO and president of Allergan.
As for merger talks, Allergan confirmed it is in early talks with the American pharmaceutical company. If the deal is made, Pfizer could add dry eye treatment Restasis and AqueSys to its arsenal of products, according to the Wall Street Journal.